US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Provectus Biopharmaceuticals, Inc.

0.0617

-0.0001-0.10%

Volume:121.95K

Turnover:7.53K

Market Cap:25.93M

PE:-4.65

High:0.0620

Open:0.0617

Low:0.0617

Close:0.0618

52wk High:0.1050

52wk Low:0.0380

Shares:420.28M

Float Shares:386.66M

Volume Ratio:2.96

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0133

EPS(LYR):-0.0213

ROE:22.69%

ROA:-501.90%

PB:-3.85

PE(LYR):-2.89

Loading ...

Overview Company News Filings

Provectus Biopharmaceuticals announces annual shareholder meeting webinar

Provectus reports oral PV-10 anti-tumor activity in preclinical bladder cancer study

Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

THOMSON REUTERS

Provectus Biopharmaceuticals Inc - Intravesical Pv-10 at 3 Mg/Dose Not Tolerated Due to Acute Mucosal Toxicity

THOMSON REUTERS

Provectus net loss widens 12% to $1.3 million in Q1 FY26

Provectus highlights REAGIR trial 12-month data for rose bengal eye infection therapy at ARVO 2026

Provectus Biopharmaceuticals announces annual shareholder meeting

Provectus highlights porcine burn study showing PV-10 shifts wounds toward reparative immune profile

Provectus Biopharmaceuticals FY2025 operating loss widens 16.8% to $(5.3) million; revenue drops 45.5% to $336,108

Provectus Biopharmaceuticals verlängert automatisches Umwandlungsdatum für Vorzugsaktien bis 2028

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PVCT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVCT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVCT\",,,,,undefined,":{"symbol":"PVCT","market":"US","secType":"STK","nameCN":"Provectus Biopharmaceuticals, Inc.","latestPrice":0.0617,"timestamp":1781711277676,"preClose":0.06176,"halted":0,"volume":121953,"delay":15,"changeRate":-0.0009715025906736479,"floatShares":386656900,"shares":420279879,"eps":-0.013279,"marketStatus":"Trading","change":-0.00006,"latestTime":"06-17 11:47:57 EDT Delay","open":0.0617,"high":0.062,"low":0.0617,"amount":7529.139920000001,"amplitude":0.004858,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.013279,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781726400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.06176,"volumeRatio":2.961792},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVCT\",,,,,undefined,":{"symbol":"PVCT","floatShares":386656900,"roa":"-501.90%","roe":"22.69%","lyrEps":-0.021324,"volumeRatio":2.961792,"shares":420279879,"dividePrice":0,"high":0.062,"amplitude":0.004858,"preClose":0.06176,"low":0.0617,"week52Low":0.038,"pbRate":"-3.85","psRate":"451.14","week52High":0.105,"institutionHeld":0.0006,"latestPrice":0.0617,"eps":-0.013279,"divideRate":0,"volume":121953,"delay":15,"ttmEps":-0.013279,"open":0.0617,"prevYearClose":0.0559,"prevWeekClose":0.0606,"prevMonthClose":0.065,"prevQuarterClose":0.0509,"fiveDayClose":0.0686,"twentyDayClose":0.0661,"sixtyDayClose":0.0509},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVCT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-08-13","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-14","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-03-28","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-22","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1708578000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVCT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVCT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVCT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2641757438","title":"Provectus Biopharmaceuticals announces annual shareholder meeting webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2641757438","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641757438?lang=en_us&edition=fundamental","pubTime":"2026-06-08 23:37","pubTimestamp":1780933079,"startTime":"0","endTime":"0","summary":"Provectus Biopharmaceuticals will hold its 2026 annual stockholder meeting in Knoxville, Tennessee on June 18, 2026.The session will include shareholder meeting business alongside a company update.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLbR6c5x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073534","title":"Provectus reports oral PV-10 anti-tumor activity in preclinical bladder cancer study","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073534","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073534?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:05","pubTimestamp":1779105942,"startTime":"0","endTime":"0","summary":"Provectus Biopharmaceuticals reported preclinical results on May 18, 2026, from a bladder cancer study testing PV-10 given orally or delivered into the bladder, alone or combined with an anti-PD-1 therapy.Oral PV-10 produced the strongest overall anti-tumor activity and tolerability signal in the study, with some animals reaching the end of the study without visible bladder tumors, a result not seen in the untreated, vehicle-control, or anti-PD-1-only groups.PV-10 delivered into the bladder was not tolerated at the concentrations used, which the company framed as a dosing limitation rather than a lack of drug activity.The update is not a clinical trial readout; Provectus identified FDA acceptance of an expanded IND to enable first-in-human oral PV-10 testing as the next regulatory milestone.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL1DhrRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD","BK4007","LU0314104364.USD","PVCT","BK4588","LU2210149790.SGD","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","IE00BKPKM429.USD","BK4112","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078786","title":"Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078786?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA7J491L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073391","title":"Provectus Biopharmaceuticals Inc - Intravesical Pv-10 at 3 Mg/Dose Not Tolerated Due to Acute Mucosal Toxicity","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073391?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA7J491L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742260","title":"Provectus net loss widens 12% to $1.3 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742260","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742260?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:53","pubTimestamp":1778781181,"startTime":"0","endTime":"0","summary":"Provectus Biopharmaceuticals posted a net loss of $1.3 million in the quarter ended March 31, 2026, widening 12%.Operating loss widened 13.7% to $1.25 million as operating expenses fell 9.3% to $1.25 million.Research and development expense dropped 17.2% to $333,334, driven by lower clinical trial and research-related costs on reduced activity levels.Grant revenue recorded no revenue versus $278,628 a year earlier, reflecting completion and full recognition of the awarded program in 2025.Cash totaled $223,883 at March 31, 2026, while working capital deficit widened to $6.78 million; management flagged substantial doubt about ability to continue as a going concern within one year without additional financing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL5vVf5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVCT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632958762","title":"Provectus highlights REAGIR trial 12-month data for rose bengal eye infection therapy at ARVO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2632958762","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632958762?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:07","pubTimestamp":1777896470,"startTime":"0","endTime":"0","summary":"Provectus flagged new research on rose bengal photodynamic antimicrobial therapy for infectious keratitis, with four posters scheduled for presentation at ARVO 2026 in Denver on May 3-7.Company also highlighted 12-month outcomes from REAGIR, a large randomized, sham-controlled trial that has already been completed and will be presented at the meeting.Overall REAGIR results showed no clear advantage from a single treatment versus control on long-term patient outcomes, pointing to protocol design as a key driver of performance.Preclinical findings to be presented support a strategy of optimizing dosing and repeat treatment, with data suggesting stronger activity under repeat or higher-intensity approaches and potential relevance for difficult-to-treat pathogens.Provectus said it plans to pursue a Phase 2b/3 trial following a pre-IND meeting for its VisiRose unit, positioning the next study as a step toward a commercial pathway for the investigational therapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL6zg2wJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","NDAQ","PVCT","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4007","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629734217","title":"Provectus Biopharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629734217","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629734217?lang=en_us&edition=fundamental","pubTime":"2026-04-21 03:31","pubTimestamp":1776713488,"startTime":"0","endTime":"0","summary":"Provectus Biopharmaceuticals scheduled 2026 annual shareholder meeting for June 18, 2026 in Knoxville, Tennessee.Shareholders will vote on election of four directors.Agenda includes advisory vote on named executive officer compensation.Items also include ratification of CBIZ CPAs as independent registered public accounting firm for 2026.Proposals cover reverse stock split for common stock, Series D Convertible Preferred Stock, Series D-1 Convertible Preferred Stock at ratio from 1-for-10 to 1-for-50, with related reduction in authorized shares tied to same ratio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL6Zv9Sr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVCT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506968","title":"Provectus highlights porcine burn study showing PV-10 shifts wounds toward reparative immune profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506968","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506968?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:03","pubTimestamp":1775131424,"startTime":"0","endTime":"0","summary":"Provectus highlighted newly published preclinical research on PV-10 in a porcine burn wound model, with results already presented in a peer-reviewed journal article.Study linked PV-10 topical dosing to a shift toward a more reparative local immune environment during later-stage healing.Findings also pointed to reduced signs of lingering inflammation without evidence of added tissue stress, supporting PV-10 positioning beyond cytotoxic or antimicrobial use.Provectus framed the data as supporting a broader platform strategy for PV-10 across wound care, with potential relevance to oncology, dermatology, and ophthalmology.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL7kCgHm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","BK4588","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4007","IE00BN0W2W23.USD","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ","PVCT","SG9999014039.USD","BK4112","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622855465","title":"Provectus Biopharmaceuticals FY2025 operating loss widens 16.8% to $(5.3) million; revenue drops 45.5% to $336,108","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855465","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622855465?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:02","pubTimestamp":1774519357,"startTime":"0","endTime":"0","summary":"Provectus Biopharmaceuticals published its annual report , reporting grant revenue of USD 336,108, down 45.5%.Operating expenses totaled USD 5.63 million, up 9.3%, with research and development expense of USD 1.9 million down 7.5% on lower clinical trial and research-related costs after certain study closures.General and administrative expense rose 20.5% to USD 3.73 million, driven mainly by higher directors’ fees, increased payroll tied to new officer appointments, higher audit-related professional fees, investor meeting travel, and NetSuite implementation costs.Net loss was USD 5.51 million, worsening 15.6%, while interest expense fell 12% to USD 210,359 due to conversions of the 2022 and 2024 notes into Series D-1 preferred stock that reduced debt balances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL5BWdWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608889761","title":"Provectus Biopharmaceuticals verlängert automatisches Umwandlungsdatum für Vorzugsaktien bis 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889761","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608889761?lang=en_us&edition=fundamental","pubTime":"2026-02-03 04:31","pubTimestamp":1770064263,"startTime":"0","endTime":"0","summary":"Provectus Biopharmaceuticals Inc. hat angekündigt, dass der Stichtag für die automatische Umwandlung der Series D und Series D-1 Convertible Preferred Stock in Stammaktien vom 20. Juni 2026 auf den 31. Dezember 2028 verschoben wird. Die nderungen wurden vom Vorstand sowie einem ausschlielich aus unabhngigen Mitgliedern bestehenden Sonderausschuss genehmigt.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL7Crx4q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVCT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}